利用方酸化学简单平台偶联方法开发靶向福氏志贺菌2a和3a型的志贺菌结合疫苗
研究开发了靶向福氏志贺菌2a型(SCV-Sf2a)和3a型(SCV-Sf3a)的结合疫苗,采用方酸化学将O特异性多糖以单点放射状展示于载体蛋白rTTHc。小鼠接种后诱导了型特异性O特异性多糖和脂多糖IgG及rTTHc特异性IgG应答,并产生型特异性杀菌抗体,且分别对福氏志贺菌2a和3a型的角结膜炎(Sereny试验)和腹腔攻击产生保护。结果支持进一步开发该平台偶联技术用于资源有限地区的志贺菌结合疫苗。
要点
- 方酸化学偶联O特异性多糖至rTTHc可形成单点放射状展示的结合疫苗。
- 小鼠接种诱导型特异性O特异性多糖和脂多糖IgG及rTTHc特异性IgG应答。
- 接种小鼠产生型特异性杀菌抗体并抵抗福氏志贺菌2a和3a型攻击。
核心结论
- 结果支持进一步开发该平台偶联技术用于资源有限地区的志贺菌结合疫苗。
研究设计与样本
- 采用方酸化学将福氏志贺菌2a和3a型的O特异性多糖偶联至载体蛋白rTTHc(破伤风类毒素重链的52 kDa重组蛋白片段)制备结合疫苗。
- 用型特异性单克隆抗体和孟加拉国志贺菌病康复者血清验证偶联物的免疫学展示。
- 小鼠接种后评估血清型特异性O特异性多糖和脂多糖IgG应答、rTTHc特异性IgG应答、杀菌抗体应答及对福氏志贺菌2a和3a型的保护。
主要发现
- 偶联物被型特异性单克隆抗体和孟加拉国志贺菌病康复者血清识别,提示O特异性多糖免疫学展示正确。
- 小鼠接种诱导型特异性O特异性多糖和脂多糖IgG应答,以及rTTHc特异性IgG应答。
- 接种诱导型特异性杀菌抗体应答,接种动物分别对福氏志贺菌2a和3a型的角结膜炎(Sereny试验)和腹腔攻击产生保护。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a need for vaccines effective against shigella infection in young children in resource-limited areas. Protective immunity against shigella infection targets the O-specific polysaccharide (OSP) component of lipopolysaccharide. Inducing immune responses to polysaccharides in young children can be problematic, but high level and durable responses can be induced by presenting polysaccharides conjugated to carrier proteins. An effective shigella vaccine will need to be multivalent, targeting the most common global species and serotypes such as Shigella flexneri 2a, S. flexneri 3a, S. flexneri 6, and S. sonnei. Here we report the development of shigella conjugate vaccines (SCV) targeting S. flexneri 2a (SCV-Sf2a) and 3a (SCV-Sf3a) using squaric acid chemistry to result in single point sun-burst type display of OSP from carrier protein rTTHc, a 52 kDa recombinant protein fragment of the heavy chain of tetanus toxoid. We confirmed structure and demonstrated that these conjugates were recognized by serotype-specific monoclonal antibodies and convalescent sera of humans recovering from shigellosis in Bangladesh, suggesting correct immunological display of OSP. We vaccinated mice and found induction of serotype-specific OSP and LPS IgG responses, as well as rTTHc-specific IgG responses. Vaccination induced serotype-specific bactericidal antibody responses against S. flexneri, and vaccinated animals were protected against keratoconjunctivitis (Sereny test) and intraperitoneal challenge with virulent S. flexneri 2a and 3a, respectively. Our results support further development of this platform conjugation technology in the development of shigella conjugate vaccines for use in resource-limited settings.
引用
- Kelly M, Mandlik A, Charles RC, et al. Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry. Vaccine. 2023. PMID: 37400283. doi:10.1016/j.vaccine.2023.06.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。